SCIENCE@home

Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study

H. T. Sørensen,Lars Pedersen,N. van Es,Harry R. Büller,E. Horváth-Puhó

Published 2023 in The Lancet Regional Health - Europe

ABSTRACT

Summary Background Despite recent improvements in the treatment of cancer, little is known about the long-term survival in patients with cancer and venous thromboembolism. We aimed to examine the five-year mortality of venous thromboembolism in cancer patients in a large population-based cohort study. Methods Using Danish healthcare registries from 1995 to 2020, we obtained data on cancer patients with venous thromboembolism and comparison cohorts of cancer patients without venous thromboembolism, matched in terms of cancer type, age, sex, and year of cancer diagnosis, and adjusted for level of comorbidity and frailty using the Charlson Comorbidity Index Score and Hospital Frailty Risk Score, marital status, use of selected medications, and recent surgery (<90 days). Findings During the study period, 886,536 patients were diagnosed with cancer. Of 1882 cancer patients diagnosed at the time of their venous thromboembolism, 44.4% (835/1882) had distant metastases. In this cohort, the one- and five-year mortality cumulative incidences were 68% (1284/1882) and 84% (1578/1882), respectively, in contrast to 38% (2135/5549) and 67% (3653/5549) in the comparison cohort. The mortality rate ratio was 4.34 (95% confidence interval [CI], 3.95–4.78) for the first year of follow-up and 3.44 (95% CI 3.17–3.73) for the five-year follow-up period. Of the 23,366 patients diagnosed with venous thromboembolism after cancer diagnosis, 18% (4183/23,366) had distant metastases at the time of cancer diagnosis. The cumulative incidence of death at one year was 45% (10,465/23,366; mortality rate ratio 3.48, 95% CI 3.37–3.60) and at five years 69% (15,669/23,366; mortality rate ratio 2.57, 95% CI 2.50–2.63). Interpretation Despite improved cancer treatment, venous thromboembolism in cancer patients is strongly associated with a poor prognosis. Funding The study was supported by grants from the 10.13039/501100004836Independent Research Fund Denmark (record no. 3101-00102B) and the 10.13039/501100004046Karen Elise Jensen Foundation.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-41 of 41 references · Page 1 of 1

CITED BY

Showing 1-64 of 64 citing papers · Page 1 of 1